Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferinject plus pulmonary rehabilitation in COPD with iron deficiency (FACE II)
2019-005005-43Phase 4Active
- Sponsor
- Parc de Salut Mar
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of ferric carboxymaltose in chronic obstructive pulmonary disease (COPD) and iron deficiency anemia (IDA), sponsored by Parc de Salut Mar. Primary endpoint: Exercise tolerance. Started Jan 2022; status: active.
02
Drugs
ferric carboxymaltose
03
Conditions
chronic obstructive pulmonary disease (COPD)iron deficiency anemia (IDA)
Beyond the preview
Go deeper on 2019-005005-43.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-005005-43.